Scivision BiotechTPE:1786 -0.56%80 PEG Ratio is 2.09 as of Jul. 09, 2026, which is 15% below its 10-year median of 2.46. GuruFocus rates TPE:1786 with a GF Score™ of 80/100 and a GF Value™ of NT$115.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 209 Medical Devices & Instruments companies, Scivision Biotech ranks worse than 51.67% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Scivision Biotech's PEG Ratio or its related term are showing as below:
TPE:1786'
s PEG Ratio Range Over the Past 10 Years
Min: 0.85 Med: 2.46 Max: 3.92
Current: 2.09
During the past 13 years, Scivision Biotech's highest PEG Ratio was 3.92. The lowest was 0.85. And the median was 2.46.
TPE:1786's PEG Ratio is ranked worse than 51.67% of 209
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs TPE:1786: 2.09
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Scivision Biotech (TPE:1786) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Scivision Biotech PEG Ratio Related Terms
Scivision Biotech PEG Ratio Historical Data
* Premium members only.
The historical data trend for Scivision Biotech's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Scivision Biotech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech PEG Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Scivision Biotech (TPE:1786) has a PEG Ratio of 2.09 as of Jul. 09, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Scivision Biotech and its competitors. This is 15% below median its historical median of 2.46. Over the past decade, Scivision Biotech's PEG Ratio has ranged from 0.85 to 3.92. According to the industry distribution chart, Scivision Biotech ranks #108 out of 209 companies in the Medical Devices & Instruments industry, placing it in the top 51.7%.
Is Scivision Biotech's PEG Ratio too high?
Scivision Biotech's current PEG Ratio of 2.09 is 15% below median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 3.92. The Medical Devices & Instruments industry median PEG Ratio is 1.89. Scivision Biotech's value of 2.09 is 10.6% above this industry median. Based on the distribution chart, Scivision Biotech ranks #108 out of 209 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's PEG Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #108 out of 209 companies for PEG Ratio. This places Scivision Biotech in the lower half of its industry. The industry median PEG Ratio is 1.89. Scivision Biotech's value of 2.09 is 10.6% above this benchmark. Historically, Scivision Biotech's own PEG Ratio has ranged from 0.85 to 3.92 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 1.89, Scivision Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 1.89, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current PEG Ratio of 2.09 is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Scivision Biotech and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current PEG Ratio is 2.09, which is 15% below median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current PEG Ratio is 2.09, which is 15% below median its 10-year median of 2.46 and 10.6% above the Medical Devices & Instruments industry median of 1.89. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current PEG Ratio is 2.09 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23.
GuruFocus considers Scivision Biotech to be Possible Value Trap.
Key valuation signals for TPE:1786:
PEG Ratio: 2.09 (15% below median its 10-year median of 2.46)
GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
Industry Position: 10.6% above the Medical Devices & Instruments median (#108 of 209)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
80GF Score
Get the complete analysis for TPE:1786
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
